Home | Welcome to Contract Pharma   
Last Updated Friday, March 27 2015

Print

Search Results for 'Financial Report: Covance'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published May 2, 2014
Late-Stage revenues up 8% in the quarter Read More »
By Gil Roth
Published February 5, 2014
Growth pushed by Late-Stage Development segment Read More »
Published October 30, 2013
Late-Stage revenues up 19% in the quarter Read More »
Published July 31, 2013
Late-Stage revenues up 17% in the quarter Read More »
Published January 25, 2013
Late-Stage revenues up 16% in the quarter Read More »
Published July 26, 2012
Late-Stage Development revenues up 13% Read More »
Published November 4, 2011
Early Development segment up 16% Read More »
Published April 29, 2010
Early development revenues were $205.0 million (+7%). Read More »
Published April 29, 2008
Covance 1Q Revenues: $434.0 million (+15%) 1Q Earnings: $49.1 million (+26%) Comments: Early development revenues were $202.0 million (+13%) led by growth of toxicology and chemistry services. Operating income increased 16% to $50.6 million.… Read More »
Published June 19, 2006
Jeffrey J. Stoddard, M.D. has been named vice president, medical and scientific affairs, risk management and postmarketing programs at Covance.  In this capacity, Dr. Stoddard will lead Covance's risk management and postmarketing business and ha… Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On